ARCHIVES

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

This article is from The Cancer Letter archive.

Vol. 32 No. 07 | February 24, 2006

Download PDF Visit The Full Archive

Related Articles

IOM Committee Focuses on Studies Needed To Protect Patients On Omics-Based Trials

November 4, 2011

ECOG, ACRIN Form Single Cooperative Group

May 18, 2012

Advocacy Groups Consider Pros And Cons Of Forming Co-Pay Foundations.

April 28, 2006

Judge Rules First Amendment Protects Distribution Of Off-Label Use Information

August 14, 1998

ASTRO Members Approve Governance, Dues Changes

January 17, 2003

NCI, NHGRI plan $100-million, three-year feasibility test for cancer genome project. NCI to establish biospecimen office.

September 23, 2005